Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 11/20 | 0.47 |
| ▸ | KDR | P35968 | 5/20 | 0.46 |
| ▸ | BRAF | P15056 | 5/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.46 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13229751 | 0.95 | MAP3K7 (0.49) | MAP3K7FLT3KDRBRAFMAPK14 | |
| SCHEMBL2794555 | 0.91 | MAP3K7 (0.47) | MAP3K7FLT3KDRBRAFMAPK14 | |
| SCHEMBL2792551 | 0.87 | MAP3K7 (0.48) | MAP3K7FLT3KDRBRAFMAPK14 | |
| SCHEMBL2790820 | 0.87 | MAP3K7 (0.62) | MAP3K7FLT3KDRBRAFMAPK14 | |
| SCHEMBL2791845 | 0.84 | FLT3 (0.53) | FLT3KDRBRAFMAPK14TNNI3K | |
| SCHEMBL2797659 | 0.82 | MAP3K7 (0.64) | MAP3K7FLT3KDRBRAFMAPK14 | |
| SCHEMBL2795248 | 0.82 | FLT3 (0.53) | FLT3KDRBRAFMAPK14TNNI3K | |
| SCHEMBL2795128 | 0.79 | FLT3 (0.55) | FLT3KDRBRAFMAPK14TNNI3K | |
| SCHEMBL2794819 | 0.78 | MAP3K7 (0.61) | MAP3K7FLT3KDRBRAFMAPK14 | |
| SCHEMBL2795404 | 0.78 | FLT3 (0.58) | FLT3KDRBRAFMAPK14TNNI3K |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1921078-B1 | MULTIKINASE INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2013-01-09 | — | — | EP | disclosed |
| US-8299252-B2 | Pyrazolopyridine and pyrrolopyridine multikinase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8299252-B2 | Pyrazolopyridine and pyrrolopyridine multikinase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8299252-B2 | Pyrazolopyridine and pyrrolopyridine multikinase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20100168430-A1 | MULTIKINASE INHIBITOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168430-A1 | MULTIKINASE INHIBITOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168430-A1 | MULTIKINASE INHIBITOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-01 | — | — | US | disclosed |
| EP-1921078-A1 | MULTIKINASE INHIBITOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168430-A1 | MULTIKINASE INHIBITOR | REN, RAF1, CHUK | MAP3K7 23/4885FLT3 217/4885KDR 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.